Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 213

1.

Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.

Petrova L, Korfiatis P, Petr O, LaChance DH, Parney I, Buckner JC, Erickson BJ.

J Neurol Sci. 2019 Aug 23;405:116433. doi: 10.1016/j.jns.2019.116433. [Epub ahead of print]

2.

Management of low-grade glioma: a systematic review and meta-analysis.

Brown TJ, Bota DA, van Den Bent MJ, Brown PD, Maher E, Aregawi D, Liau LM, Buckner JC, Weller M, Berger MS, Glantz M.

Neurooncol Pract. 2019 Jul;6(4):249-258. doi: 10.1093/nop/npy034. Epub 2018 Aug 18. Review.

PMID:
31386075
3.

Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma.

Ruff MW, Buckner JC, Johnson DR, van den Bent MJ, Geurts M.

Neurooncol Pract. 2019 Jan;6(1):17-21. doi: 10.1093/nop/npy044. Epub 2018 Nov 3. Review.

PMID:
31386006
4.

A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.

Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D.

Cancer. 2019 Nov 1;125(21):3790-3800. doi: 10.1002/cncr.32340. Epub 2019 Jul 10.

PMID:
31290996
5.

Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology.

Alliance Cancer in the Older Adult Committee, Adjei A, Buckner JC, Cathcart-Rake E, Chen H, Cohen HJ, Dao D, De Luca JE, Feliciano J, Freedman RA, Goldberg RM, Hopkins J, Hubbard J, Jatoi A, Karuturi M, Kemeny M, Kimmick GG, Klepin HD, Krok-Schoen JL, Lafky JM, Le-Rademacher JG, Li D, Lichtman SM, Maggiore R, Mandelblatt J, Morrison VA, Muss HB, Ojelabi MO, Sedrak MS, Subbiah N, Sun V, Tuttle S, VanderWalde N, Wildes T, Wong ML, Woyach J.

J Geriatr Oncol. 2019 Jun 11. pii: S1879-4068(19)30158-4. doi: 10.1016/j.jgo.2019.05.011. [Epub ahead of print] Review. No abstract available.

PMID:
31201095
6.

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E.

J Neurooncol. 2019 Jul;143(3):583. doi: 10.1007/s11060-019-03201-3.

7.

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E.

J Neurooncol. 2019 Jul;143(3):573-581. doi: 10.1007/s11060-019-03194-z. Epub 2019 May 22. Erratum in: J Neurooncol. 2019 Jun 5;:.

PMID:
31119479
8.

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?

Tom MC, Cahill DP, Buckner JC, Dietrich J, Parsons MW, Yu JS.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:133-145. doi: 10.1200/EDBK_238353. Epub 2019 May 17.

PMID:
31099638
9.

Controversies in the Therapy of Low-Grade Gliomas.

Carabenciov ID, Buckner JC.

Curr Treat Options Oncol. 2019 Mar 14;20(4):25. doi: 10.1007/s11864-019-0625-6. Review.

PMID:
30874903
10.

Spindle cell rhabdomyosarcoma of bone with FUS-TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype.

Dashti NK, Wehrs RN, Thomas BC, Nair A, Davila J, Buckner JC, Martinez AP, Sukov WR, Halling KC, Howe BM, Folpe AL.

Histopathology. 2018 Sep;73(3):514-520. doi: 10.1111/his.13649. Epub 2018 Jun 29.

PMID:
29758589
11.

A phylogenomic perspective on the robust capuchin monkey (Sapajus) radiation: First evidence for extensive population admixture across South America.

Lima MGM, Silva-Júnior JSE, Černý D, Buckner JC, Aleixo A, Chang J, Zheng J, Alfaro ME, Martins A, Di Fiore A, Boubli JP, Lynch Alfaro JW.

Mol Phylogenet Evol. 2018 Jul;124:137-150. doi: 10.1016/j.ympev.2018.02.023. Epub 2018 Mar 12.

PMID:
29545109
12.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

Schiff D, Jaeckle KA, Anderson SK, Galanis E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ, Schwerkoske JF, Kaluza V, Twohy E, Dancey J, Wright J, Sarkaria JN.

Cancer. 2018 Apr 1;124(7):1455-1463. doi: 10.1002/cncr.31219. Epub 2018 Jan 3.

13.

Mitogenomics supports an unexpected taxonomic relationship for the extinct diving duck Chendytes lawi and definitively places the extinct Labrador Duck.

Buckner JC, Ellingson R, Gold DA, Jones TL, Jacobs DK.

Mol Phylogenet Evol. 2018 May;122:102-109. doi: 10.1016/j.ympev.2017.12.008. Epub 2017 Dec 13.

PMID:
29247849
14.

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF.

Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175. Review.

15.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

16.

Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial.

Churilla TM, Ballman KV, Brown PD, Twohy EL, Jaeckle K, Farace E, Cerhan JH, Anderson SK, Carrero XW, Garces YI, Barker FG 2nd, Deming R, Dixon JG, Burri SH, Chung C, Ménard C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1173-1178. doi: 10.1016/j.ijrobp.2017.07.045. Epub 2017 Aug 5.

17.

The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.

Youland RS, Kreofsky CR, Schomas DA, Brown PD, Buckner JC, Laack NN.

J Neurooncol. 2017 Dec;135(3):535-543. doi: 10.1007/s11060-017-2599-1. Epub 2017 Aug 23.

PMID:
28836106
18.

Residual Deep Convolutional Neural Network Predicts MGMT Methylation Status.

Korfiatis P, Kline TL, Lachance DH, Parney IF, Buckner JC, Erickson BJ.

J Digit Imaging. 2017 Oct;30(5):622-628. doi: 10.1007/s10278-017-0009-z.

19.

Optimal radiotherapy target volumes in intracranial nongerminomatous germ cell tumors: Long-term institutional experience with chemotherapy, surgery, and dose- and field-adapted radiotherapy.

Breen WG, Blanchard MJ, Rao AN, Daniels DJ, Buckner JC, Laack NNI.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26637. Epub 2017 Jul 11.

PMID:
28695992
20.

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.

Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D.

Lancet Oncol. 2017 Aug;18(8):1049-1060. doi: 10.1016/S1470-2045(17)30441-2. Epub 2017 Jul 4.

21.

Adjuvant nitrosoureas: will they ever go away?

Buckner JC.

Neuro Oncol. 2017 Feb 1;19(2):145-146. doi: 10.1093/neuonc/now268. No abstract available.

22.

Radiation plus Chemotherapy in Low-Grade Glioma.

Buckner JC, Chakravarti A, Curran WJ Jr.

N Engl J Med. 2016 Aug 4;375(5):490-1. doi: 10.1056/NEJMc1605897. No abstract available.

PMID:
27518677
23.

Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.

Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG 2nd, Deming R, Burri SH, Ménard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL.

JAMA. 2016 Jul 26;316(4):401-409. doi: 10.1001/jama.2016.9839. Erratum in: JAMA. 2018 Aug 7;320(5):510.

24.

MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas.

Korfiatis P, Kline TL, Coufalova L, Lachance DH, Parney IF, Carter RE, Buckner JC, Erickson BJ.

Med Phys. 2016 Jun;43(6):2835-2844. doi: 10.1118/1.4948668.

25.

Pragmatic study designs for older adults with cancer: Report from the U13 conference.

Nipp RD, Yao NA, Lowenstein LM, Buckner JC, Parker IR, Gajra A, Morrison VA, Dale W, Ballman KV.

J Geriatr Oncol. 2016 Jul;7(4):234-41. doi: 10.1016/j.jgo.2016.02.005. Epub 2016 Jul 5. Review.

PMID:
27197914
26.

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ Jr.

N Engl J Med. 2016 Apr 7;374(14):1344-55. doi: 10.1056/NEJMoa1500925.

27.

Seizures in patients with primary brain tumors: what is their psychosocial impact?

Shin JY, Kizilbash SH, Robinson SI, Uhm JH, Hammack JE, Lachance DH, Buckner JC, Jatoi A.

J Neurooncol. 2016 Jun;128(2):285-91. doi: 10.1007/s11060-016-2108-y. Epub 2016 Mar 15.

PMID:
26979915
28.

QOL and Survival Comparisons by Race in Oncology Clinical Trials.

Tan AD, Novotny PJ, Kaur JS, Buckner JC, Mowat RB, Paskett E, Sloan JA.

J Cancer Clin Oncol. 2016 Mar-Aug;2(1). pii: 100112. Epub 2016 Nov 16.

29.

Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance).

Brown PD, Anderson SK, Carrero XW, O'Neill BP, Giannini C, Galanis E, Shah SA, Abrams RA, Curran WJ Jr, Buckner JC, Shaw EG.

Neurooncol Pract. 2015 Dec;2(4):199-204. Epub 2015 Aug 6.

30.

Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients.

Liu H, Tan AD, Qin R, Sargent DJ, Grothey A, Buckner JC, Schaefer PL, Sloan JA.

SOJ Anesthesiol Pain Manag. 2015;2(2). doi: 10.15226/2374-684X/2/2/00120. Epub 2015 Apr 10.

31.

Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression.

Kelm ZS, Korfiatis PD, Lingineni RK, Daniels JR, Buckner JC, Lachance DH, Parney IF, Carter RE, Erickson BJ.

J Med Imaging (Bellingham). 2015 Apr;2(2):026001. doi: 10.1117/1.JMI.2.2.026001. Epub 2015 May 26.

32.

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB.

N Engl J Med. 2015 Jun 25;372(26):2499-508. doi: 10.1056/NEJMoa1407279. Epub 2015 Jun 10.

33.

Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma?

Laack NN, Sarkaria JN, Buckner JC.

Semin Radiat Oncol. 2015 Jul;25(3):197-202. doi: 10.1016/j.semradonc.2015.02.004. Epub 2015 Feb 21. Review.

34.

Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature.

Kourelis TV, Buckner JC, Gangat N, Patnaik MM.

Am J Hematol. 2015 Sep;90(9):E183-4. doi: 10.1002/ajh.24066. Epub 2015 Jul 22. No abstract available.

35.

Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.

Berg AK, Buckner JC, Galanis E, Jaeckle KA, Ames MM, Reid JM.

J Clin Pharmacol. 2015 Nov;55(11):1303-12. doi: 10.1002/jcph.543. Epub 2015 Jun 26.

36.

Success, significance, and social responsibility.

Buckner JC.

Neuro Oncol. 2015 May;17(5):629-30. doi: 10.1093/neuonc/nov030. Epub 2015 Mar 16. No abstract available.

37.

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System.

Brat DJ, Cagle PT, Dillon DA, Hattab EM, McLendon RE, Miller MA, Buckner JC; Members of the Cancer Biomarker Reporting Committee, College of American Pathologists.

Arch Pathol Lab Med. 2015 Sep;139(9):1087-93. doi: 10.5858/arpa.2014-0588-CP. Epub 2015 Feb 2. No abstract available.

PMID:
25642959
38.

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.

Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Ligon KL, Buckner JC, Sarkaria JN.

Neuro Oncol. 2015 Sep;17(9):1261-9. doi: 10.1093/neuonc/nou328. Epub 2014 Dec 18.

39.

Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales.

Singh JA, Satele D, Pattabasavaiah S, Buckner JC, Sloan JA.

Health Qual Life Outcomes. 2014 Dec 18;12:187. doi: 10.1186/s12955-014-0187-z.

40.

Impact of imaging measurements on response assessment in glioblastoma clinical trials.

Reardon DA, Ballman KV, Buckner JC, Chang SM, Ellingson BM.

Neuro Oncol. 2014 Oct;16 Suppl 7:vii24-35. doi: 10.1093/neuonc/nou286.

41.

Clinical outcomes of children and adults with central nervous system primitive neuroectodermal tumor.

Lester RA, Brown LC, Eckel LJ, Foote RT, NageswaraRao AA, Buckner JC, Parney IF, Wetjen NM, Laack NN.

J Neurooncol. 2014 Nov;120(2):371-9. doi: 10.1007/s11060-014-1561-8. Epub 2014 Aug 13.

PMID:
25115737
42.

The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.

Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Hardie J, Laack NN, Parney IF, Uhm JH, Buckner JC.

J Neurooncol. 2014 Oct;120(1):85-93. doi: 10.1007/s11060-014-1520-4. Epub 2014 Jul 4.

43.

Biogeography of the marmosets and tamarins (Callitrichidae).

Buckner JC, Lynch Alfaro JW, Rylands AB, Alfaro ME.

Mol Phylogenet Evol. 2015 Jan;82 Pt B:413-25. doi: 10.1016/j.ympev.2014.04.031. Epub 2014 May 20.

PMID:
24857784
44.

Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice.

Hubbard JM, Grothey AF, McWilliams RR, Buckner JC, Sloan JA.

J Oncol Pract. 2014 Jul;10(4):248-53. doi: 10.1200/JOP.2013.001276. Epub 2014 Mar 25.

45.

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ Jr.

J Clin Oncol. 2014 Mar 10;32(8):783-90. doi: 10.1200/JCO.2013.49.3726. Epub 2014 Feb 10.

46.

Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.

Prabhu RS, Won M, Shaw EG, Hu C, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP.

J Clin Oncol. 2014 Feb 20;32(6):535-41. doi: 10.1200/JCO.2013.53.1830. Epub 2014 Jan 13.

47.

Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival.

Van Gompel JJ, Giannini C, Olsen KD, Moore E, Piccirilli M, Foote RL, Buckner JC, Link MJ.

J Neurol Surg B Skull Base. 2012 Oct;73(5):331-6. doi: 10.1055/s-0032-1321512.

48.

New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials.

Gorlia T, Wu W, Wang M, Baumert BG, Mehta M, Buckner JC, Shaw E, Brown P, Stupp R, Galanis E, Lacombe D, van den Bent MJ.

Neuro Oncol. 2013 Nov;15(11):1568-79. doi: 10.1093/neuonc/not117. Epub 2013 Sep 18.

49.

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.

Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC.

Clin Cancer Res. 2013 Sep 1;19(17):4816-23. doi: 10.1158/1078-0432.CCR-13-0708. Epub 2013 Jul 5.

50.

Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years.

Youland RS, Schomas DA, Brown PD, Nwachukwu C, Buckner JC, Giannini C, Parney IF, Laack NN.

Neuro Oncol. 2013 Aug;15(8):1102-10. doi: 10.1093/neuonc/not080. Epub 2013 Jun 27.

Supplemental Content

Loading ...
Support Center